New York University;Salk Institute for Biological Studies
发明人:
Moosa Mohammadi,Regina M. Goetz,Ronald M. Evans,Michael Downes,Jae Myoung Suh
申请号：
US14176992
公开号：
US08999929B2
申请日:
2014.02.10
申请国别(地区):
US
年份:
2015
代理人:
摘要：
The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF19 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the βKlotho-FGF receptor complex involving the use of chimeric proteins of the present invention.
